Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Risk
Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Related publications
Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 3a in Pakistani Population - A Real World Experience
Pakistan Journal of Medical Sciences
Medicine
Daclatasvir and Sofosbuvir With Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients With Cirrhosis: A Phase III Study (ALLY-3C)
Antiviral Therapy
Infectious Diseases
Pharmacology
Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus
Hepatology
Medicine
Hepatology
Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis
Digestive Diseases and Sciences
Physiology
Gastroenterology
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
JAMA - Journal of the American Medical Association
Medicine
Sofosbuvir, Ribavirin and Pegylated Interferon for a Daclatasvir-Resistent Genotype 3 Hepatitis C Virus: Case Report and Review
Revista do Instituto de Medicina Tropical de Sao Paulo
Medicine
Infectious Diseases
Association of IL-1β, IL-1RN, and ESR1 Genes Polymorphism With Risk of Infection and Response to Sofosbuvir Plus Daclatasvir Combination Therapy in Hepatitis C Virus Genotype-4 Patients
IUBMB Life
Biochemistry
Genetics
Clinical Biochemistry
Cell Biology
Molecular Biology
Efficacy and Safety of Generic Daclatasvir + Sofosbuvir ± Ribavirin in Treatment of Genotype 3 Infected Hepatitis C Patients - A Real Life Experience From Pakistan
Hepatoma Research
Cost-Effectiveness Analysis of Sofosbuvir Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: An Analysis With Real World Outcomes From a Multicentre Cohort in Japan
BMJ Open
Medicine
